CLINICAL_TRIALS
trial_result
· 2021-02-11
Clinical Trial Update: Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer [Phase 2]
Summary
Phase 2 trial updating pembrolizumab for recurrent or metastatic medullary thyroid cancer has completed with results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Cancer Institute (NCI) | Conditions: Medullary Thyroid Cancer (MTC) | Phase 2 | Status: COMPLETED | Results posted: 2021-02-11